Regulation of mitosis and taxane response by Daxx and Rassf1 (original) (raw)

• Aapro MS . (2001). Neoadjuvant therapy in breast cancer: can we define its role? Oncologist 6 (Suppl 3): 36–39.
  Article CAS Google Scholar
• Agathanggelou A, Cooper WN, Latif F . (2005). Role of the Ras-association domain family 1 tumor suppressor gene in human cancers. Cancer Res 65: 3497–3508.
  Article CAS Google Scholar
• Amaar YG, Baylink DJ, Mohan S . (2005). Ras-association domain family 1 protein, RASSF1C, is an IGFBP-5 binding partner and a potential regulator of osteoblast cell proliferation. J Bone Miner Res 20: 1430–1439.
  Article CAS Google Scholar
• Bonneterre J, Spielman M, Guastalla JP, Marty M, Viens P, Chollet P et al. (1999). Efficacy and safety of docetaxel (Taxotere) in heavily pretreated advanced breast cancer patients: the French compassionate use programme experience. Eur J Cancer 35: 1431–1439.
  Article CAS Google Scholar
• Brito DA, Rieder CL . (2006). Mitotic checkpoint slippage in humans occurs via cyclin B destruction in the presence of an active checkpoint. Curr Biol 16: 1194–1200.
  Article CAS Google Scholar
• Carvalho A, Carmena M, Sambade C, Earnshaw WC, Wheatley SP . (2003). Survivin is required for stable checkpoint activation in taxol-treated HeLa cells. J Cell Sci 116: 2987–2998.
  Article CAS Google Scholar
• Chabalier C, Lamare C, Racca C, Privat M, Valette A, Larminat F . (2006). BRCA1 downregulation leads to premature inactivation of spindle checkpoint and confers paclitaxel resistance. Cell Cycle 5: 1001–1007.
  Article CAS Google Scholar
• Chang JC, Wooten EC, Tsimelzon A, Hilsenbeck SG, Gutierrez MC, Elledge R et al. (2003). Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet 362: 362–369.
  Article CAS Google Scholar
• Chang JC, Wooten EC, Tsimelzon A, Hilsenbeck SG, Gutierrez MC, Tham YL et al. (2005). Patterns of resistance and incomplete response to docetaxel by gene expression profiling in breast cancer patients. J Clin Oncol 23: 1169–1177.
  Article CAS Google Scholar
• Crown J, O'Leary M, Ooi WS . (2004). Docetaxel and paclitaxel in the treatment of breast cancer: a review of clinical experience. Oncologist 9 (Suppl 2): 24–32.
  Article CAS Google Scholar
• Dallol A, Agathanggelou A, Fenton SL, Ahmed-Choudhury J, Hesson L, Vos MD et al. (2004). RASSF1A interacts with microtubule-associated proteins and modulates microtubule dynamics. Cancer Res 64: 4112–4116.
  Article CAS Google Scholar
• De Mulder PH . (1999). The chemotherapy of head and neck cancer. Acta Otorhinolaryngol Belg 53: 247–252.
  CAS PubMed Google Scholar
• Escobar-Cabrera E, Lau DK, Giovinazzi S, Ishov AM, McIntosh LP . (2010). Structural characterization of the DAXX N-terminal helical bundle domain and its complex with Rassf1C. Structure 18: 1642–1653.
  Article CAS Google Scholar
• Estrabaud E, Lassot I, Blot G, Le Rouzic E, Tanchou V, Quemeneur E et al. (2007). RASSF1C, an isoform of the tumor suppressor RASSF1A, promotes the accumulation of beta-catenin by interacting with betaTrCP. Cancer Res 67: 1054–1061.
  Article CAS Google Scholar
• Hari M, Wang Y, Veeraraghavan S, Cabral F . (2003a). Mutations in alpha- and beta-tubulin that stabilize microtubules and confer resistance to colcemid and vinblastine. Mol Cancer Ther 2: 597–605.
  CAS PubMed Google Scholar
• Hari M, Yang H, Zeng C, Canizales M, Cabral F . (2003b). Expression of class III beta-tubulin reduces microtubule assembly and confers resistance to paclitaxel. Cell Motil Cytoskeleton 56: 45–56.
  Article CAS Google Scholar
• Henderson IC, Berry DA, Demetri GD, Cirrincione CT, Goldstein LJ, Martino S et al. (2003). Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 21: 976–983.
  Article CAS Google Scholar
• Ishov AM, Sotnikov AG, Negorev D, Vladimirova OV, Neff N, Kamitani T et al. (1999). PML is critical for ND10 formation and recruits the PML-interacting protein daxx to this nuclear structure when modified by SUMO-1. J Cell Biol 147: 221–234.
  Article CAS Google Scholar
• Ishov AM, Vladimirova OV, Maul GG . (2004). Heterochromatin and ND10 are cell-cycle regulated and phosphorylation-dependent alternate nuclear sites of the transcription repressor Daxx and SWI/SNF protein ATRX. J Cell Sci 117: 3807–3820.
  Article CAS Google Scholar
• Iwao-Koizumi K, Matoba R, Ueno N, Kim SJ, Ando A, Miyoshi Y et al. (2005). Prediction of docetaxel response in human breast cancer by gene expression profiling. J Clin Oncol 23: 422–431.
  Article CAS Google Scholar
• Kitagawa D, Kajiho H, Negishi T, Ura S, Watanabe T, Wada T et al. (2006). Release of RASSF1C from the nucleus by Daxx degradation links DNA damage and SAPK/JNK activation. EMBO J 25: 3286–3297.
  Article CAS Google Scholar
• Kubota T, Matsuzaki SW, Hoshiya Y, Watanabe M, Kitajima M, Asanuma F et al. (1997). Antitumor activity of paclitaxel against human breast carcinoma xenografts serially transplanted into nude mice. J Surg Oncol 64: 115–121.
  Article CAS Google Scholar
• Lee EA, Keutmann MK, Dowling ML, Harris E, Chan G, Kao GD . (2004). Inactivation of the mitotic checkpoint as a determinant of the efficacy of microtubule-targeted drugs in killing human cancer cells. Mol Cancer Ther 3: 661–669.
  CAS PubMed Google Scholar
• Lens SM, Wolthuis RM, Klompmaker R, Kauw J, Agami R, Brummelkamp T et al. (2003). Survivin is required for a sustained spindle checkpoint arrest in response to lack of tension. EMBO J 22: 2934–2947.
  Article CAS Google Scholar
• Lindsay CR, Giovinazzi S, Ishov AM . (2009). Daxx is a predominately nuclear protein that does not translocate to the cytoplasm in response to cell stress. Cell Cycle 8: 1544–1551.
  Article CAS Google Scholar
• Lindsay CR, Morozov VM, Ishov AM . (2008). PML NBs (ND10) and Daxx: from nuclear structure to protein function. Front Biosci 13: 7132–7142.
  Article CAS Google Scholar
• Lindsay CR, Scholz A, Morozov VM, Ishov AM . (2007). Daxx shortens mitotic arrest caused by paclitaxel. Cell Cycle 6: 1200–1204.
  Article CAS Google Scholar
• Liu L, Baier K, Dammann R, Pfeifer GP . (2007). The tumor suppressor RASSF1A does not interact with Cdc20, an activator of the anaphase-promoting complex. Cell Cycle 6: 1663–1665.
  Article CAS Google Scholar
• Liu L, Tommasi S, Lee DH, Dammann R, Pfeifer GP . (2003). Control of microtubule stability by the RASSF1A tumor suppressor. Oncogene 22: 8125–8136.
  Article CAS Google Scholar
• Mantel C, Guo Y, Lee MR, Han MK, Rhorabough S, Kim KS et al. (2008). Cells enter a unique intermediate 4_N_ stage, not 4_N_-G1, after aborted mitosis. Cell Cycle 7: 484–492.
  Article CAS Google Scholar
• Mauriac L, Debled M, MacGrogan G . (2005). When will more useful predictive factors be ready for use? Breast 14: 617–623.
  Article Google Scholar
• Meraldi P, Draviam VM, Sorger PK . (2004). Timing and checkpoints in the regulation of mitotic progression. Dev Cell 7: 45–60.
  Article CAS Google Scholar
• Michaelson JS . (2000). The Daxx enigma. Apoptosis 5: 217–220.
  Article CAS Google Scholar
• Michaelson JS, Bader D, Kuo F, Kozak C, Leder P . (1999a). Loss of Daxx, a promiscuously interacting protein, results in extensive apoptosis in early mouse development. Genes Dev 13: 1918–1923.
  Article CAS Google Scholar
• Michaelson JS, Bader D, Kuo F, Kozak C, Leder P . (1999b). Loss of daxx, a promiscuously interacting protein, results in extensive apoptosis in early mouse development [In Process Citation]. Genes Dev 13: 1918–1923.
  Article CAS Google Scholar
• Miyoshi Y, Kim SJ, Akazawa K, Kamigaki S, Ueda S, Yanagisawa T et al. (2004). Down-regulation of intratumoral aromatase messenger RNA levels by docetaxel in human breast cancers. Clin Cancer Res 10: 8163–8169.
  Article CAS Google Scholar
• Morozov VM, Massoll NA, Vladimirova OV, Maul GG, Ishov AM . (2008). Regulation of c-met expression by transcription repressor Daxx. Oncogene 27: 2177–2186.
  Article CAS Google Scholar
• Niikura Y, Dixit A, Scott R, Perkins G, Kitagawa K . (2007). BUB1 mediation of caspase-independent mitotic death determines cell fate. J Cell Biol 178: 283–296.
  Article CAS Google Scholar
• Nilsson J, Yekezare M, Minshull J, Pines J . (2008). The APC/C maintains the spindle assembly checkpoint by targeting Cdc20 for destruction. Nat Cell Biol 10: 1411–1420.
  Article CAS Google Scholar
• O'Shaughnessy J . (2005). Extending survival with chemotherapy in metastatic breast cancer. Oncologist 10 (Suppl 3): 20–29.
  Article CAS Google Scholar
• Ravdin P, Erban J, Overmoyer B . (2003). Phase III comparison of docetaxel and paclitaxel in patients with metastatic breast cancer (abstract). Eur J Cancer (Suppl 1): 32.
• Rong R, Jiang LY, Sheikh MS, Huang Y . (2007). Mitotic kinase Aurora-A phosphorylates RASSF1A and modulates RASSF1A-mediated microtubule interaction and M-phase cell cycle regulation. Oncogene 26: 7700–7708.
  Article CAS Google Scholar
• Rong R, Jin W, Zhang J, Sheikh MS, Huang Y . (2004). Tumor suppressor RASSF1A is a microtubule-binding protein that stabilizes microtubules and induces G2/M arrest. Oncogene 23: 8216–8230.
  Article CAS Google Scholar
• Sablina AA, Budanov AV, Ilyinskaya GV, Agapova LS, Kravchenko JE, Chumakov PM . (2005). The antioxidant function of the p53 tumor suppressor. Nat Med 11: 1306–1313.
  Article CAS Google Scholar
• Saffert RT, Kalejta RF . (2008). Promyelocytic leukemia-nuclear body proteins: herpesvirus enemies, accomplices, or both? Fut Virol 3: 265–277.
  Article CAS Google Scholar
• Salomoni P, Khelifi AF . (2006). Daxx: death or survival protein? Trends Cell Biol 16: 97–104.
  Article CAS Google Scholar
• Scolnick DM, Halazonetis TD . (2000). Chfr defines a mitotic stress checkpoint that delays entry into metaphase. Nature 406: 430–435.
  Article CAS Google Scholar
• Song MS, Song SJ, Ayad NG, Chang JS, Lee JH, Hong HK et al. (2004). The tumour suppressor RASSF1A regulates mitosis by inhibiting the APC–Cdc20 complex. Nat Cell Biol 6: 129–137.
  Article CAS Google Scholar
• Song MS, Song SJ, Kim SY, Oh HJ, Lim DS . (2008). The tumour suppressor RASSF1A promotes MDM2 self-ubiquitination by disrupting the MDM2–DAXX–HAUSP complex. EMBO J 27: 1863–1874.
  Article CAS Google Scholar
• Sudo T, Nitta M, Saya H, Ueno NT . (2004). Dependence of paclitaxel sensitivity on a functional spindle assembly checkpoint. Cancer Res 64: 2502–2508.
  Article CAS Google Scholar
• Summers MK, Pan B, Mukhyala K, Jackson PK . (2008). The unique N terminus of the UbcH10 E2 enzyme controls the threshold for APC activation and enhances checkpoint regulation of the APC. Mol Cell 31: 544–556.
  Article CAS Google Scholar
• Swanton C, Marani M, Pardo O, Warne PH, Kelly G, Sahai E et al. (2007). Regulators of mitotic arrest and ceramide metabolism are determinants of sensitivity to paclitaxel and other chemotherapeutic drugs. Cancer Cell 11: 498–512.
  Article CAS Google Scholar
• Wang Y, Cabral F . (2005). Paclitaxel resistance in cells with reduced beta-tubulin. Biochim Biophys Acta 1744: 245–255.
  Article CAS Google Scholar
• Wassmann K, Benezra R . (2001). Mitotic checkpoints: from yeast to cancer. Curr Opin Genet Dev 11: 83–90.
  Article CAS Google Scholar
• Wysong DR, Chakravarty A, Hoar K, Ecsedy JA . (2009). The inhibition of Aurora A abrogates the mitotic delay induced by microtubule perturbing agents. Cell Cycle 8: 876–888.
  Article CAS Google Scholar
• Xia G, Luo X, Habu T, Rizo J, Matsumoto T, Yu H . (2004). Conformation-specific binding of p31(comet) antagonizes the function of Mad2 in the spindle checkpoint. EMBO J 23: 3133–3143.
  Article CAS Google Scholar